79
Pharma & HealthcareStrong Buy
HDFC Pharma And Healthcare
HDFC · Direct–Growth · rank #2 of 19 by Smart Score
Data updated
Trailing returns
1 Year
31.6%
+30.8% vs index
3 Years
30.6%
+19.0% vs index
5 Years
—
Since launch
31.6%
Year-by-year performance
2024
+52.2%+36.6% vs index
2025
+2.4%-5.3% vs index
2026
+32.8%+31.9% vs index
Why this score
HDFC Pharma And Healthcare scores 79/100 — #2 of 19 Pharma & Healthcare fund (Strong Buy). It stands out for 3y return and sharpe ratio — beating 96% of peers on 3y return. The main drag is its volatility (better than only 22% of peers).
Each bar shows the fund's percentile vs Pharma & Healthcare peers — a longer bar beats more of the category.
3Y return30.55% · 96th percentile in category
Sharpe ratio1.40 · 97th percentile in category
Sortino ratio2.40 · 97th percentile in category
Volatility16.19 · 22nd percentile in category
Alpha8.94 · 84th percentile in category
Fund size3661.87 Cr · 76th percentile in category
Top holdings
1.Divi's Laboratories Ltd9.44%
2.Sun Pharmaceutical Industries Ltd7.74%
3.Dr. Reddy's Laboratories Ltd6.66%
4.Apollo Hospitals Enterprise Ltd5.19%
5.Alkem Laboratories Ltd4.75%
38 disclosed equity positions · portfolio as of Oct 2026 · weights are % of total corpus.